RNA antisense oligonucleotide for intravitreal injection ( DrugBank: - )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
90	網膜色素変性症	1
303	アッシャー症候群	1

90. 網膜色素変性症

---

臨床試験数 : 147 /  薬物数 : 176 - (DrugBank : 43) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 110

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05085964 (ClinicalTrials.gov)	September 16, 2021	7/10/2021	An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa	An Open-Label Extension Study to Evaluate the Safety and Tolerability of QR 421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Helia)	Retinitis Pigmentosa;Usher Syndrome Type 2	Drug: RNA antisense oligonucleotide for intravitreal injection	ProQR Therapeutics	NULL	Terminated	12 Years	N/A	All	21	Phase 2	United States;Canada;France

303. アッシャー症候群

---

臨床試験数 : 10 /  薬物数 : 11 - (DrugBank : 0) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05085964 (ClinicalTrials.gov)	September 16, 2021	7/10/2021	An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa	An Open-Label Extension Study to Evaluate the Safety and Tolerability of QR 421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Helia)	Retinitis Pigmentosa;Usher Syndrome Type 2	Drug: RNA antisense oligonucleotide for intravitreal injection	ProQR Therapeutics	NULL	Terminated	12 Years	N/A	All	21	Phase 2	United States;Canada;France